Omeros (NASDAQ:OMER) Shares Up 5.5% – Should You Buy?

Omeros Co. (NASDAQ:OMER)’s stock price was up 5.5% during trading on Thursday . The stock traded as high as $9.49 and last traded at $9.39. Approximately 200,332 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 617,175 shares. The stock had previously closed at $8.90.

Analyst Upgrades and Downgrades

OMER has been the topic of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research report on Friday. RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Finally, Rodman & Renshaw started coverage on shares of Omeros in a research note on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Performance

The firm has a fifty day simple moving average of $9.35 and a two-hundred day simple moving average of $6.00. The firm has a market cap of $540.67 million, a PE ratio of -4.04 and a beta of 2.01.

Hedge Funds Weigh In On Omeros

Institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets grew its position in Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 7,016 shares in the last quarter. Seros Financial LLC purchased a new position in shares of Omeros in the 4th quarter worth approximately $159,000. MML Investors Services LLC increased its position in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 3,000 shares during the last quarter. SPC Financial Inc. bought a new stake in Omeros in the third quarter worth $77,000. Finally, SG Americas Securities LLC purchased a new position in Omeros during the third quarter worth $80,000. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.